Učitavanje...
Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer
BACKGROUND: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond to EGFRi comb...
Spremljeno u:
| Izdano u: | BMC Med Genomics |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5069826/ https://ncbi.nlm.nih.gov/pubmed/27756306 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-016-0225-2 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|